Stock Analysis of Acrivon Therapeutics Inc. (ACRV) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ACRV
Close 8.89
Change 0.330 / 3.86 %
Volume 58398.00
Vol Change 16716.00 / 40.10 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthBullish
Growth Index Very Low Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index No Significant Stability


Fundamental View of Acrivon Therapeutics Inc.
PE (TTM)

-763.90

Very Poor
Price / Book

361.75

Very Poor
Price / Sales

25997.63

Very Poor
Piotroski F Score

1.0

Very Poor
Market Cap

274483 K

Enterprise Value

239345 K

ROA (TTM)

-43.32

Very Poor
ROE (TTM)

-47.36

Very Poor
Net Margin (TTM)

-3403.29

Very Poor
Revenue

%

0
Net Profit

60.63 %

-50065.00 K
Debt to Equity

0.0072

Excellent
Altman Z Score

8.28

Excellent
Quick Ratio

0

Poor
Cash Ratio

9.58

Excellent


Highs/Lows of Acrivon Therapeutics Inc.
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week8.77 1.37 % 1.54 % 9.18.1513-May-2414-May-24
Two Week9.59 7.30 % 3.42 % 9.587.9806-May-2410-May-24
One Month10.34 14.02 % 5.60 % 11.517.818-Apr-2425-Apr-24
Three Month3.94 125.63 % 5.95 % 11.93.4509-Apr-2420-Feb-24
Six Months3.89 128.53 % 17.48 % 11.93.1909-Apr-2413-Feb-24
One year13.5 34.15 % 27.52 % 14.033.1921-Jun-2313-Feb-24


Technical View of Acrivon Therapeutics Inc.
RSI

53.15

Neutral
MACD

0.128

Bearish
ADX

33.55

Mild Bullish
Super Trend

7.04

Mild Bullish
Williams %R

-60.61

Neutral
CCI

-3.51

Neutral


EMA 5

8.66

Strong Bullish
EMA 15

8.67

Strong Bullish
EMA 50

7.87

Bullish
EMA 100

7.13

Bullish
SMA 100

6.08

Bullish
SMA 200

6.88

Strong Bullish
SMA 5 / 20

8.59 / 8.82

Mild Bearish
SMA 15 / 50

8.71 / 7.85

Bullish
SMA 50 / 200

7.85 / 6.88

Strong Bullish




Charts of Acrivon Therapeutics Inc.


Returns of Acrivon Therapeutics Inc. with Peers
Period / StockACRVCRMDVMDBDTX
1 Week1.37%-0.967%-0.490%-20.29%
1 Mth-14.02%-5.88%-9.08%-14.56%
3 Mth125.63%54.68%-17.90%-8.97%
6mth128.53%27.68%-7.30%127.57%
1 Year-34.15%17.03%-32.03%181.50%
2 Year-34.03%25.18%147.21%
5 Years--30.15%5.00%-
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Acrivon Therapeutics Inc. with Peers
Ratio / StockACRVCRMDVMDBDTX
PE-763.90-0.019027.50-792.64
P/B361.750.01233.04590.26
ROA-43.32-56.887.87-54.73
ROE-47.36-64.669.50-74.47
Debt To Equity0.00720.00210.0700.0267
Revenue0
% 		29702.00
54.59 % 		169777 K
22.29 % 		0
%
Net Income-50065.00 K
60.63 % 		-39794.15 K
33.98 % 		9204.00 K
47.93 % 		-82442.00 K
90327.67 %


Technicals of Acrivon Therapeutics Inc. with Peers
Technical / StockACRVCRMDVMDBDTX-
ADX33.5538.9725.0330.55
CMF-0.185-0.188-0.098-0.267
MFI45.2640.3936.5229.88
RSI53.1547.0535.4738.19
MACD Abv SignalFalseFalseFalseFalse
Price Above 50 MATrueTrueFalseFalse-
Price Above 200 MATrueTrueFalseTrue-


About : Acrivon Therapeutics Inc. Common Stock

Address : 480 Arsenal Way, Watertown, MA, United States, 02472
Tel : 617 207 8979
URL : https://www.acrivon.com
Code : ACRV, ISIN : US0048901096, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 15_Nov_2022
Employee Count : 58

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.


Note : All Data Generated at the End of Trading Hours (EOD Data)